EU court prepares to tackle legal wrangles over SPCs
This article was originally published in SRA
Europe's supplementary protection certificates have proved a useful way of extending effective patent life for pharmaceutical products, but as with many other forms of intellectual property protection, uncertainties in the legislation have given rise to many legal disputes. Unfortunately progress in clarifying the situation has been slow, and several cases are still pending before the national and European courts.
You may also be interested in...
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.
Coronavirus Notebook: EMA Issues Guidance On Development Of Variant Vaccines, EU Leaders Urge Production Ramp-Up
A batch of AstraZeneca/Oxford University coronavirus vaccines has arrived in Ghana, the first country in the world to receive vaccines via the COVAX Facility.